# NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
Canonical URL: https://biopharmsignal.com/news/NRSN/neurosense-therapeutics-announces-receipt-of-nasdaq-notifications-regarding-minimum-bid-price-and-market-value-requirements
Ticker: NRSN
Company: NeuroSense Therapeutics
Source: NeuroSense Therapeutics
Published: 2026-04-03 14:02 EST
Original Source URL: https://neurosense.investorroom.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-22 12:30 EST — [NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS](https://biopharmsignal.com/news/NRSN/neurosense-advances-primec-toward-new-drug-submission-to-health-canada-for-als-721c198c) — Source: NeuroSense Therapeutics
- 2026-07-06 12:45 EST — [NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"](https://biopharmsignal.com/news/NRSN/neurosense-to-participate-in-roth-hosted-kol-webinar-on-the-future-of-als-treatm-467c5922) — Source: NeuroSense Therapeutics
- 2026-06-29 13:30 EST — [NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS](https://biopharmsignal.com/news/NRSN/neurosense-achieves-primary-endpoint-in-phase-2b-als-study-with-statistically-si-6471ada3) — Source: NeuroSense Therapeutics
- 2026-06-25 13:20 EST — [NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease](https://biopharmsignal.com/news/NRSN/neurosense-reports-positive-biomarker-findings-from-phase-2-road-proof-of-concep-8751aee3) — Source: NeuroSense Therapeutics
- 2026-06-22 13:00 EST — [EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots](https://biopharmsignal.com/news/NRSN/everythingals-to-host-neurosense-in-a-community-event-named-primec-connecting-th-d3cba239) — Source: NeuroSense Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)